{
    "root": "27426bc1-4084-4e2f-a06f-05830677d2a3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Felbamate",
    "value": "20250317",
    "ingredients": [
        {
            "name": "FELBAMATE",
            "code": "X72RBB02N8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4995"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "felbamate tablets usp indicated first line antiepileptic treatment ( ) . felbamate tablets usp recommended patients respond inadequately alternative treatments whose epilepsy severe substantial risk aplastic anemia and/or liver failure deemed acceptable light benefits conferred . criteria met patient fully advised risk , provided written acknowledgement , felbamate tablets usp considered either monotherapy adjunctive therapy treatment partial seizures , without generalization , adults epilepsy adjunctive therapy treatment partial generalized seizures associated lennox-gastaut syndrome children .",
        "doid_entities": [
            {
                "text": "epilepsy (DOID:1826)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1826"
            },
            {
                "text": "aplastic anemia (DOID:12449)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12449"
            },
            {
                "text": "anemia (DOID:2355)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2355"
            },
            {
                "text": "lennox-gastaut syndrome (DOID:0050561)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050561"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "lennox-gastaut syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_2382"
            }
        ]
    },
    "contraindications": {
        "text": "felbamate tablets studied monotherapy adjunctive therapy adults adjunctive therapy children seizures associated lennox-gastaut syndrome . felbamate tablets added substituted existing aeds , strongly recommended reduce aeds range 20 33 % minimize side effects ( subsection ) . adjustment renally impaired : felbamate used caution patients renal dysfunction . renally impaired , starting maintenance doses reduced one-half ( pharmacology / pharmacokinetics ) . adjunctive therapy medications affect felbamate plasma concentrations , especially aeds , may warrant reductions felbamate daily doses patients renal dysfunction . adults ( 14 years age ) majority patients received 3600 mg/day trials evaluating monotherapy adjunctive therapy . monotherapy : ( initial therapy ) felbamate tablets systematically evaluated initial monotherapy . initiate felbamate tablets 1200 mg/day divided doses three four times daily . prescriber advised titrate previously untreated patients close supervision , increasing 600-mg increments every 2 weeks 2400 mg/day based response thereafter 3600 mg/day clinically indicated . conversion monotherapy : initiate felbamate tablets 1200 mg/day divided doses three four times daily . reduce concomitant aeds one-third initiation felbamate tablets therapy . week 2 , increase felbamate tablets 2400 mg/day reducing aeds additional one-third original . week 3 , increase felbamate tablets 3600 mg/day continue reduce aeds clinically indicated . adjunctive therapy : felbamate tablets added 1200 mg/day divided doses three four times daily reducing present aeds 20 % order control plasma concentrations concurrent phenytoin , valproic acid , phenobarbital , carbamazepine metabolites . reductions concomitant aeds may necessary minimize side effects due . increase felbamate tablets 1200 mg/day increments weekly intervals 3600 mg/day . side effects seen felbamate tablets adjunctive therapy resolve concomitant aeds decreased . table 6 table ( adults ) reduction concomitant aeds week 1 reduce original dose 20 33 % * week 2 reduce original dose additional 1/3 * week 3 reduce clinically indicated felbamate tablets 1200 mg/day initial dose 2400 mg/day therapeutic range 3600 mg/day therapeutic range * adjunctive conversion monotherapy sections . felbamate tablets conversion guidelines may result felbamate tablets 3600 mg/day dose within 3 weeks , patients titration 3600 mg/day felbamate tablets dose achieved little 3 days appropriate adjustment aeds . children lennox-gastaut syndrome ( ages 2 14 years ) adjunctive therapy : felbamate tablets added 15 mg/kg/day divided doses three four times daily reducing present aeds 20 % order control plasma levels concurrent phenytoin , valproic acid , phenobarbital , carbamazepine metabolites . reductions concomitant aeds may necessary minimize side effects due . increase felbamate tablets 15 mg/kg/day increments weekly intervals 45 mg/kg/day . side effects seen felbamate tablets adjunctive therapy resolve concomitant aeds decreased .",
        "doid_entities": [
            {
                "text": "lennox-gastaut syndrome (DOID:0050561)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050561"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "lennox-gastaut syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_2382"
            }
        ]
    },
    "warningsAndPrecautions": "felbamate tablets usp , 600 mg , light yellow yellow , capsule shaped tablets debossed \u2018 ani 731 \u2019 one side bisect side . bottles 100 ndc 63629-1944-1 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense tight container . report susected , contact fda 1-800-fda-1088 www.fda.gov/medwatch . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "felbamate contraindicated patients known hypersensitivity felbamate , ingredients , known sensitivity carbamates . used patients history blood dyscrasia hepatic dysfunction .",
    "indications_original": "Felbamate Tablets USP\u00a0are not indicated as a first line antiepileptic treatment (see\u00a0\n                        WARNINGS\n                     ).\u00a0Felbamate Tablets USP\u00a0are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.\n                  If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgement, Felbamate Tablets USP\u00a0can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.",
    "contraindications_original": "Felbamate\u00a0tablets\u00a0have been studied as monotherapy and adjunctive therapy in adults and as adjunctive therapy in children with seizures associated with Lennox-Gastaut syndrome. As\u00a0felbamate tablets\u00a0are added to or substituted for existing AEDs, it is strongly recommended to reduce the dosage of those AEDs in the range of 20 to 33% to minimize side effects (see\u00a0\n                        Drug Interactions\u00a0\n                     subsection).\n                  \n                     Dosage Adjustment in the Renally Impaired: Felbamate should be used with caution in patients with renal dysfunction. In the renally impaired, starting and maintenance doses should be reduced by one-half (see\u00a0\n                        CLINICAL PHARMACOLOGY / Pharmacokinetics\n                     \u00a0and \n                        PRECAUTIONS\n                     ). Adjunctive therapy with medications which affect felbamate plasma concentrations, especially AEDs, may warrant further reductions in felbamate daily doses in patients with renal dysfunction.\n                  \n                     \n                        Adults (14 years of age and over)\n                     \n                  \n                  The majority of patients received 3600 mg/day in clinical trials evaluating its use as both monotherapy and adjunctive therapy.\n                  \n                     \n                        Monotherapy:\u00a0\n                     (Initial therapy)\u00a0Felbamate tablets\u00a0have not been systematically evaluated as initial monotherapy. Initiate\u00a0felbamate tablets\u00a0at 1200 mg/day in divided doses three or four times daily. The prescriber is advised to titrate previously untreated patients under close clinical supervision, increasing the dosage in 600-mg increments every 2 weeks to 2400 mg/day based on clinical response and thereafter to 3600 mg/day if clinically indicated.\n                  \n                     \n                        Conversion to Monotherapy:\n                      Initiate\u00a0felbamate tablets\u00a0at 1200 mg/day in divided doses three or four times daily. Reduce the dosage of concomitant AEDs by one-third at initiation of\u00a0felbamate tablets therapy. At week 2, increase the\u00a0felbamate tablets dosage to 2400 mg/day while reducing the dosage of other AEDs up to an additional one-third of their original dosage. At week 3, increase the\u00a0felbamate tablets dosage up to 3600 mg/day and continue to reduce the dosage of other AEDs as clinically indicated.\n                  \n                     \n                        Adjunctive Therapy:\n                     \u00a0Felbamate tablets\u00a0should be added at 1200 mg/day in divided doses three or four times daily while reducing present AEDs by 20% in order to control plasma concentrations of concurrent phenytoin, valproic acid, phenobarbital, and carbamazepine and its metabolites. Further reductions of the concomitant AEDs dosage may be necessary to minimize side effects due to drug interactions. Increase the dosage of\u00a0felbamate tablets\u00a0by 1200 mg/day increments at weekly intervals to 3600 mg/day. Most side effects seen during\u00a0felbamate tablets\u00a0adjunctive therapy resolve as the dosage of concomitant AEDs is decreased.\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Table 6 Dosage Table (adults)\n                              \n                           \n                        \n                        \n                           \n                              Dosage reduction of concomitant AEDs\n                           \n                           \n                              \n                                 WEEK 1\n                                 REDUCE original dose by 20 to 33%*\n                           \n                           \n                              \n                                 WEEK 2\n                                 REDUCE original dose by up to an additional 1/3*\n                           \n                           \n                              \n                                 WEEK 3\n                                 REDUCE as clinically indicated\n                           \n                        \n                        \n                           \n                              Felbamate Tablets Dosage\n                           \n                           \n                              1200 mg/day Initial dose\n                           \n                           \n                              2400 mg/day Therapeutic dosage range\n                           \n                           \n                              3600 mg/day Therapeutic dosage range\n                           \n                        \n                        \n                           \n                              *See \n                                    Adjunctive \n                                 and\n                                     Conversion to Monotherapy\n                                  sections.\n                           \n                        \n                     \n                  \n                  While the above\u00a0felbamate tablets\u00a0conversion guidelines may result in a\u00a0felbamate tablets\u00a03600 mg/day dose within 3 weeks, in some patients titration to a 3600 mg/day\u00a0felbamate tablets\u00a0dose has been achieved in as little as 3 days with appropriate adjustment of other AEDs.\n                  \n                     \n                        Children with Lennox-Gastaut Syndrome (Ages 2 to 14 years)\n                     \n                  \n                  \n                     \n                        Adjunctive Therapy:\n                     \u00a0Felbamate tablets\u00a0should be added at 15 mg/kg/day in divided doses three or four times daily while reducing present AEDs by 20% in order to control plasma levels of concurrent phenytoin, valproic acid, phenobarbital, and carbamazepine and its metabolites. Further reductions of the concomitant AEDs dosage may be necessary to minimize side effects due to drug interactions. Increase the dosage of\u00a0felbamate tablets\u00a0by 15 mg/kg/day increments at weekly intervals to 45 mg/kg/day. Most side effects seen during\u00a0felbamate tablets\u00a0adjunctive therapy resolve as the dosage of concomitant AEDs is decreased.",
    "warningsAndPrecautions_original": "Felbamate Tablets USP, 600 mg, are light yellow to yellow, capsule shaped tablets debossed \u2018ANI 731\u2019on one side and bisect on the other side.\n                  \n                     Bottles of 100 NDC\u00a063629-1944-1\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Dispense in tight container.\n                  \n                     To report SUSECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\n                  \n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Felbamate\u00a0is contraindicated in patients with known hypersensitivity to felbamate, its ingredients, or known sensitivity to other carbamates. It should not be used in patients with a history of any blood dyscrasia or hepatic dysfunction.",
    "drug": [
        {
            "name": "Felbamate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4995"
        }
    ]
}